Patent application number | Description | Published |
20080220450 | Population Based Prediction Methods for Immune Response Determinations and Methods for Verifying Immunological Response Data - The present invention provides means to assess immune response profiles of populations. In particular, the present invention provides means to qualitatively assess the immune response of human populations, wherein the immune response directed against any protein of interest is analyzed. The present invention further provides means to rank proteins based on their relative immunogenicity. In further embodiments, the present invention provides means for verifying immunological response data, as well as means for predicting immune responses directed against any antigen/immunogen. In addition, the present invention provides means to create proteins with reduced immunogenicity for use in various applications. | 09-11-2008 |
20090035798 | Methods for Reducing the Immunogenicity of Cytokines and Removal of Cell Surface Markers - The present invention provides means to assess the comparative allergenicity of proteases. In particular, the present invention provides means to qualitatively assess the potential for any protease to induce an allergic response in humans. In addition, the present invention provides means to select proteases with reduced allergenicity for use in various applications. | 02-05-2009 |
20090060933 | PROTEASES PRODUCING AN ALTERED IMMUNOGENIC RESPONSE AND METHODS OF MAKING AND USING THE SAME - The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins. | 03-05-2009 |
20090258380 | Perhydrolase Epitopes - The present invention provides perhydrolase enzyme CD4+ T-cell epitopes, as well as variants that exhibit reduced immunogenic responses, as compared to the parental perhydrolase . The present invention further provides DNA molecules that encode perhydrolase variants, and host cells comprising DNA encoding perhydrolase variants, as well as methods for making perhydrolase enzymes less immunogenic. In addition, the present invention provides various compositions that comprise perhydrolase variants that are less immunogenic than the wild-type perhydrolase. In some specific embodiments, the present invention provides perhydrolase variants with reduced immunogenicity identified and/or characterized using the methods of the present invention. These enzymes find use in cleaning and other applications. In some preferred embodiments, the present invention finds particular use in applications involving cleaning, bleaching and disinfecting. | 10-15-2009 |
20090258832 | Cytokines and Cytokine Receptors With Reduced Immunocencity - The present invention provides methods for the identification of CD4 | 10-15-2009 |
20100266613 | ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES - The present invention relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of TNF-α. | 10-21-2010 |
20100291150 | PSEUDOMONAS EXOTOXIN A CD4+ T-CELL EPITOPES - The present invention provides PE CD4+ T-cell epitopes, as well as novel variants that exhibit reduced immunogenic responses, as compared to the parental PE. The present invention further provides DNA molecules that encode novel PE variants, host cells comprising DNA encoding novel PE variants, as well as methods for making PEs less immunogenic. In addition, the present invention provides various compositions that comprise these PE variants that are less immunogenic than wild-type PEs. | 11-18-2010 |
20100322931 | ANTI-VEGF ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF. | 12-23-2010 |
20110076260 | Proteases Producing an Altered Immunogenic Response and Methods of Making and Using the Same - The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins. | 03-31-2011 |
20110160440 | Cab Molecules - The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in diagnosis and therapy. | 06-30-2011 |
20110177095 | ANTI-HER2 ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to HER2 and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of HER2. | 07-21-2011 |
20110263517 | Cytokines and Cytokine Receptors with Reduced Immunogenicity - The present invention provides methods for the identification of CD4+ T-cell epitopes in the sequences of various proteins, namely, human cytokines and cytokine receptors, as well as the production of peptides which when incorporated into the protein sequence, are no longer capable of initiating the CD4+ T-cell response. In some embodiments, the present invention provides means and compositions suitable for reducing the immunogenicity of cytokines and cytokines receptors such as interferon-β, soluble tumor necrosis factor receptor-1, erythoropoietin, and thrombopoietin. | 10-27-2011 |
20120107314 | CAB MOLECULES - The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy. | 05-03-2012 |
20120135005 | ANTI-TNF-a ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-α. | 05-31-2012 |
20130216519 | PROTEASES PRODUCING AN ALTERED IMMUNOGENIC RESPONSE AND METHODS OF MAKING AND USING THE SAME - The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins. | 08-22-2013 |
20130217093 | PERHYDROLASE EPITOPES - The present invention provides perhydrolase enzyme CD4+ T-cell epitopes, as well as novel variants that exhibit reduced immunogenic responses, as compared to the parental perhydrolase. The present invention further provides DNA molecules that encode novel perhydrolase variants, and host cells comprising DNA encoding novel perhydrolase variants, as well as methods for making perhydrolase enzymes less immunogenic. In addition, the present invention provides various compositions that comprise perhydrolase variants that are less immunogenic than the wild-type perhydrolase. In some specific embodiments, the present invention provides perhydrolase variants with reduced immunogenicity identified and/or characterized using the methods of the present invention. These enzymes find use in cleaning and other applications. In some preferred embodiments, the present invention finds particular use in applications involving cleaning, bleaching and disinfecting. | 08-22-2013 |
20140186922 | PROTEASES PRODUCING AN ALTERED IMMUNOGENIC RESPONSE AND METHODS OF MAKING AND USING THE SAME - The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins. | 07-03-2014 |
20140212424 | ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES - The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-α. | 07-31-2014 |
20140294881 | PROTEASES PRODUCING AN ALTERED IMMUNOLOGICAL RESPONSE AND METHODS OF MAKING AND USING THE SAME - The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins. | 10-02-2014 |
20140377253 | FC VARIANTS - The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors. | 12-25-2014 |